Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review

References

• Sanikommu SR, Reese ES, He J, et al. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation. J Clin Apher. 2021 Aug;36(4):553–562.
   PubMed Web of Science ®Google Scholar
• Vishnu P, Roy V, Paulsen A, et al. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion. 2012 Jan;52(1):55–62.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Wolf RC, Micallef IN, et al. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant. 2010 Sep;45(9):1396–1403.
   PubMed Web of Science ®Google Scholar
• Pierelli L, Perseghin P, Marchetti M, et al. Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. Transfusion. 2012 Apr;52(4):893–905.
   PubMed Web of Science ®Google Scholar
• Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol blood marrow transplant. 2014 Mar;20(3):295–308.
   PubMed Web of Science ®Google Scholar
• Mohty M, Hübel K, Kröger N, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European group for blood and marrow transplantation. Bone Marrow Transplant. 2014;49(7):865–872.
   PubMed Web of Science ®Google Scholar
• Douglas KW, Gilleece M, Hayden P, et al. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. J Clin Apher. 2018 Feb;33(1):46–59.
   PubMed Web of Science ®Google Scholar
• Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008 Sep;14(9):1045–1056.
   PubMed Web of Science ®Google Scholar
• Kurnaz F, Kaynar L. Peripheral blood stem cell mobilization failure. Transfus Apher Sci. 2015 Aug;53(1):3–7.
   PubMed Web of Science ®Google Scholar
• Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014 Jan;28(1):31–40.
   PubMed Web of Science ®Google Scholar
• Pornprasertsud N, Niparuck P, Kidkarn R, et al. The use of hematocrit level for predicting the efficiency of peripheral blood CD34 + cell collection after G-CSF mobilization in healthy donors. J Clin Apher. 2015 Dec;30(6):329–334.
   PubMed Web of Science ®Google Scholar
• Hsu JW, Wingard JR, Logan BR, et al. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2015 Jan;21(1):165–171.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:4767–4773. United States.
   PubMed Web of Science ®Google Scholar
• Cooper DL, Medoff E, Patel N, et al. Autologous stem cell mobilization in the age of plerixafor. Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):411–416.
   PubMed Web of Science ®Google Scholar
• Hartmann T, Hübel K, Monsef I, et al. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma. Cochrane Database Syst Rev. 2015 Oct 20;2015:Cd010615.
   PubMedGoogle Scholar
• Yang X, Wan M, Yu F, et al. Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: a systematic review and meta-analysis. Exp Ther Med. 2019 Aug;18(2):1141–1148.
   PubMed Web of Science ®Google Scholar
• Luo C, Wu G, Huang X, et al. Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2022 Mar 22;13(1):123.
   PubMed Web of Science ®Google Scholar
• Lor KW, Helmons PJ, Belew H, et al. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin’s lymphoma or multiple myeloma. Pharmacotherapy. 2012 Jul;32(7):596–603.
   PubMed Web of Science ®Google Scholar
• Tanhehco YC, Vogl DT, Stadtmauer EA, et al. The evolving role of plerixafor in hematopoietic progenitor cell mobilization. Transfusion. 2013 Oct;53(10):2314–2326.
   PubMed Web of Science ®Google Scholar
• Li J, Hamilton E, Vaughn L, et al. Effectiveness and cost analysis of “just-in-time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 2011 Oct;51(10):2175–2182.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2013 Jan;19(1):87–93.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 2011 Jan;46(1):64–69.
   PubMed Web of Science ®Google Scholar
• Tichopád A, Vítová V, Kořístek Z, et al. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients. J Clin Apher. 2013 Dec;28(6):395–403.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1;4(1):1.
   PubMed Web of Science ®Google Scholar
• JBI. Joanna Briggs Institute reviewers’ Manual: 2014 edition/supplement. The Systematic Review of Economic Evaluation Evidence. The Joanna Briggs Institute; 2014.
   Google Scholar
• Cochrane handbook for systematic reviews of interventions version 6.3. Cochrane; 2022 [cited Feb 2022]. Available from: www.training.cochrane.org/handbook
   Google Scholar
• Shields GE, Elvidge J. Challenges in synthesising cost-effectiveness estimates. Syst Rev. 2020 Dec 9;9(1):289.
   PubMed Web of Science ®Google Scholar
• Gomersall JS, Jadotte YT, Xue Y, et al. Conducting systematic reviews of economic evaluations. Int J Evid Based Healthc. 2015 Sep;13(3):170–178.
   PubMedGoogle Scholar
• Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy J Res Pract. 2010;6(1):51–59
   Google Scholar
• Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355–371.
   PubMed Web of Science ®Google Scholar
• Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005 March;21(2):240–245.
   PubMed Web of Science ®Google Scholar
• Kim SS, Renteria AS, Steinberg A , et al. Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma. Cytotherapy. 2014 Nov;16(11):1584–1589.
   PubMed Web of Science ®Google Scholar
• Kymes SM, Pusic I, Lambert DL, et al. Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care. 2012 Jan;18(1):33–41.
   PubMed Web of Science ®Google Scholar
• Veltri L, Cumpston A, Shillingburg A, et al. Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor use. Cytotherapy. 2015 Dec;17(12):1785–1792.
   PubMed Web of Science ®Google Scholar
• Shah EE, Young RP, Wong SW , et al. Impact of plerixafor use at different peripheral blood CD34+ thresholds on autologous stem cell collection in patients with multiple myeloma. Biol blood marrow transplant. 2020 May;26(5):876–883.
   PubMed Web of Science ®Google Scholar
• Hsu YM, Cushing MM. Autologous stem cell mobilization and collection. Hematol Oncol Clin North Am. 2016 Jun;30(3):573–589.
   PubMed Web of Science ®Google Scholar
• Donmez A, Arik B, Tombuloglu M, et al. Risk factors for adverse events during collection of peripheral blood stem cells. Transfus Apher Sci. 2011 Aug;45(1):13–16.
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Huang Y, Abraham I, et al. Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. Leuk Res. 2019 Oct;85:106215.
   PubMed Web of Science ®Google Scholar
• Chow E, Rao KV, Wood WA, et al. Effectiveness of an algorithm-based approach to the utilization of plerixafor in patients undergoing chemotherapy-based stem cell mobilization. Biol Blood Marrow Transplant. 2014;20(7):1064–1068.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Karami M, Mayor J, et al. The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells. J Clin Apher. 2012;27(2):81–87.
   PubMed Web of Science ®Google Scholar
• Smith VR, Popat U, Ciurea S, et al. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol. 2013 Sep;88(9):754–757.
   PubMed Web of Science ®Google Scholar
• Abhyankar S, DeJarnette S, Aljitawi O, et al. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant. 2012 Apr;47(4):483–487.
   PubMed Web of Science ®Google Scholar
• LaPorte J, Solomon SR, Bashey A, et al. An effective hematopoietic stem cell mobilization algorithm for adding plerixafor to G-CSF for multiple myeloma patients undergoing autologous transplantation. Blood. 2011;118(21):4389.
   Google Scholar
• Kaczor MP, Wójcik R, Pawlik D, et al. PSY42 - cost-effectiveness of plerixafor (PXF) for stem cell mobilization in lymphoma (NHL/HL) and Multiple Myeloma (MM) patients in Poland. Value Health. 2013 November 01;16(7):A384–A5.
   Web of Science ®Google Scholar
• Salinas G, Idrovo J, Zapata L. PCN70 economic evaluation on the use of plerixafor alongside the Granulocyte-Colony Stimulating Factor (GCSF) in preparation for an autologous hematopoietic stem cell transplantation on patients with non hodgkin’s lymphoma. Value Health. 2010 May 01;13(3):A36–7.
   Web of Science ®Google Scholar
• Krysanova V, Krysanov I. PCN195 - the comparative pharmacoeconomic analysis of using plerixafor for stem cell mobilization for autologous peripheral stem cell transplantation for Non-Hodgkin’s lymphoma patients. Value Health. 2015 November 01;18(7):A464.
   Web of Science ®Google Scholar
• Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess. 2004 Dec;8(49):iii–iv, 1–192.
   PubMed Web of Science ®Google Scholar